Paraneoplastic retinopathy and optic neuropathy

Brain and Nerve

Volumn 62, Issue 4, 2010, Pages 371-376

  Ikawa, Masamichi ^a   Kuriyama, Masaru ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Cancer associated retinopathy; Melanoma associated retinopathy; Paraneoplastic optic neuropathy; Paraneoplastic retinopathy; Recoverin

Indexed keywords

AUTOANTIBODY; COLLAPSIN RESPONSE MEDIATOR PROTEIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 5; COLLAPSIN RESPONSE MEDIATOR PROTEIN 5 ANTIBODY; CORTICOSTEROID; IMMUNOGLOBULIN; RECOVERIN; RECOVERIN ANTIBODY; UNCLASSIFIED DRUG;

CANCER ASSOCIATED RETINOPATHY; CLINICAL FEATURE; COLOR VISION; ELECTRORETINOGRAPHY; ENCEPHALOMYELITIS; HUMAN; LUNG SMALL CELL CANCER; MELANOMA; MELANOMA ASSOCIATED RETINOPATHY; OPHTHALMOPLEGIA; OPTIC NERVE DISEASE; PAPILLEDEMA; PARANEOPLASTIC NEUROPATHY; PHOTORECEPTOR; PHOTOSENSITIVITY; PLASMAPHERESIS; PROGNOSIS; RETINA CONE; RETINA ROD; RETINITIS; RETINOPATHY; SCOTOMA; SHORT SURVEY; VISUAL ACUITY; VISUAL IMPAIRMENT;

AUTOANTIBODIES; DIAGNOSIS, DIFFERENTIAL; HUMANS; LUNG NEOPLASMS; MELANOMA; NERVE TISSUE PROTEINS; OPTIC NERVE DISEASES; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM; PROGNOSIS; RECOVERIN; RETINAL DISEASES; SMALL CELL LUNG CARCINOMA;

EID: 77951519964     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (46)

1. Posner JB: Paraneoplastic syndromes. In Neurologic Complications of Cancer. F A Davis, Philadelphia, 1995, pp353-385
2. Volpe NJ, Rizzo JF 3rd: Retinal disease in neuroophthalmology: paraneoplastic retinopathy and the big blind spot syndrome. Semin Ophthalmol 10: 234-241, 1995
3. Dropcho EJ: Neurologic paraneoplastic syndromes. J Neurol Sci 153: 264-278, 1998
4. Keltner JL, Thirkill CE: Cancer-associated retinopathy vs recoverin-associated retinopathy. Am J Ophthalmol 126: 296-302, 1998
5. Ko MW, Dalmau J, Galetta SL: Neuro-ophthalmologic manifestations of paraneoplastic syndromes. J Neuroophthalmol 28: 58-68, 2008
6. Sawyer RA, Selhorst JB, Zimmerman LE, Hoyt WF: Blindness caused by photoreceptor degeneration as a remote effect of cancer. Am J Ophthalmol 81: 606-613, 1976
7. Keltner JL, Roth AM, Chang RS: Photoreceptor degeneration. Possible autoimmune disorder. Arch Ophthalmol 101: 564-569, 1983
8. Thirkill CE, FitzGerald P, Sergott RC, Roth AM, Tyler NK, et al: Cancer-associated retinopathy (CAR syndrome) with antibodies reacting with retinal, optic-nerve, and cancer cells. N Engl J Med 321: 1589-1594, 1989
9. Polans AS, Burton MD, Haley TL, Crabb JW, Palczewski K: Recoverin, but not visinin, is an autoantigen in the human retina identified with a cancer-associated retinopathy. Invest Ophthalmol Vis Sci 34: 81-90, 1993
10. Dizhoor AM, Ray S, Kumar S, Niemi G, Spencer M, et al: Recoverin: a calcium sensitive activator of retinal rod guanylate cyclase. Science 251: 915-918, 1991
11. Dizhoor AM, Chen CK, Olshevskaya E, Sinelnikova VV, Phillipov P, et al: Role of the acylated amino terminus of recoverin in Ca (2+)-dependent membrane interaction. Science 259: 829-832, 1993
12. Kawamura S, Murakami M: Calcium-dependent regulation of cyclic GMP phosphodiesterase by a protein from frog retinal rods. Nature 349: 420-423, 1991
13. Ohguro H, Rudnicka-Nawrot M, Buczyłko J, Zhao X, Taylor JA, et al: Structural and enzymatic aspects of rhodopsin phosphorylation. J Biol Chem 271: 5215-5224, 1996
14. Polans AS, Witkowska D, Haley TL, Amundson D, Baizer L, et al: Recoverin, a photoreceptor-specific calcium-binding protein, is expressed by the tumor of a patient with cancer-associated retinopathy. Proc Natl Acad Sci U S A 92: 9176-9180, 1995
15. Ohguro H, Maruyama I, Nakazawa M, Oohira A: Antirecoverin antibody in the aqueous humor of a patient with cancer-associated retinopathy. Am J Ophthalmol 134: 605-607, 2002
16. Ohguro H, Ogawa K, Maeda T, Maeda A, Maruyama I: Cancer-associated retinopathy induced by both anti-recoverin and anti-hsc70 antibodies in vivo. Invest Ophthalmol Vis Sci 40: 3160-3167, 1999
17. Adamus G, Aptsiauri N, Guy J, Heckenlively J, Flannery J, et al: The occurrence of serum autoantibodies against enolase in cancer-associated retinopathy. Clin Immunol Immunopathol 78: 120-129, 1996
18. Whitcup SM, Vistica BP, Milam AH, Nussenblatt RB, Gery I: Recoverin-associated retinopathy: a clinically and immunologically distinctive disease. Am J Ophthalmol 126: 230-237, 1998
19. Heckenlively JR, Ferreyra HA: Autoimmune retinopathy: a review and summary. Semin Immunopathol 30: 127-134, 2008
20. Berson EL, Lessell S: Paraneoplastic night blindness with malignant melanoma. Am J Ophthalmol 106: 307-311, 1988
21. Keltner JL, Thirkill CE, Yip PT: Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuroophthalmol 21: 173-187, 2001
22. Milam AH, Saari JC, Jacobson SG, Lubinski WP, Feun LG, et al: Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy. Invest Ophthalmol Vis Sci 34: 91-100, 1993
23. Weinstein JM, Kelman SE, Bresnick GH, Kornguth SE: Paraneoplastic retinopathy associated with antiretinal bipolar cell antibodies in cutaneous malignant melanoma. Ophthalmology 101: 1236-1243, 1994
24. Cross SA, Salomao DR, Parisi JE, Kryzer TJ, Bradley EA, et al: Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 54: 38-50, 2003
25. Charrier E, Reibel S, Rogemond V, Aguera M, Thomasset N, et al: Collapsin response mediator proteins (CRMPs): involvement in nervous system development and adult neurodegenerative disorders. Mol Neurobiol 28: 51-64, 2003
26. Honnorat J, Antoine JC, Derrington E, Aguera M, Belin MF: Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 61: 270-278, 1996
27. Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, et al: CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 49: 146-154, 2001
28. Arés-Luque A, García-Tuñón LA, Saiz A, Cabezas BC, Hernández-Echebarrla LE, et al: Isolated paraneoplastic optic neuropathy associated with small-cell lung cancer and anti-CV2 antibodies. J Neurol 254: 1131-1132, 2007
29. Honnorat J, Cartalat-Carel S, Ricard D, Camdessanche JP, Carpentier AF, et al: Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 80: 412-416, 2009
30. Ohguro H, Yokoi Y, Ohguro I, Mamiya K, Ishikawa F, et al: Clinical and immunologic aspects of cancer-associated retinopathy. Am J Ophthalmol 137: 1117-1119, 2004
31. Jacobson DM, Thirkill CE, Tipping SJ: A clinical triad to diagnose paraneoplastic retinopathy. Ann Neurol 28: 162-167, 1990
32. Scaravilli F, An SF, Groves M, Thom M: The neuropathology of paraneoplastic syndromes. Brain Pathol 9: 251-260, 1999
33. Boeck K, Hofmann S, Klopfer M, Ian U, Schmidt T, et al: Melanoma-associated paraneoplastic retinopathy: case report and review of the literature. Br J Dermatol 137: 457-460, 1997 (Pubitemid 27421581)
34. Andréasson S, Ponjavic V, Ehinger B: Full-field electroretinogram in a patient with cutaneous melanoma-associated retinopathy. Acta Ophthalmol 71: 487-490, 1993
35. Pillay N, Gilbert JJ, Ebers GC, Brown JD: Internuclear ophthalmoplegia and "optic neuritis": paraneoplastic effects of bronchial carcinoma. Neurology 34: 788-791, 1984
36. Boghen D, Sebag M, Michaud J: Paraneoplastic optic neuritis and encephalomyelitis. Report of a case. Arch Neurol 45: 353-356, 1988
37. Thambisetty MR, Scherzer CR, Yu Z, Lennon VA, Newman NJ: Paraneoplastic optic neuropathy and cerebellar ataxia with small cell carcinoma of the lung. J Neuroophthalmol 21: 164-167, 2001
38. Sheorajpanday R, Slabbynck H, Van De Sompel W, Galdermans D, Neetens I, et al: Small cell lung carcinoma presenting as collapsin response-mediating protein (CRMP) -5 paraneoplastic optic neuropathy. J Neuroophthalmol 26: 168-172, 2006
39. Ducray F, Roos-Weil R, Garcia PY, Slesari J, Heinzlef O, et al: Devic's syndrome-like phenotype associated with thymoma and anti-CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 78: 325-327, 2007
40. Guy J, Aptsiauri N: Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases. Arch Ophthalmol 117: 471-477, 1999
41. Subhadra C, Dudek AZ, Rath PP, Lee MS: Improvement in visual fields in a patient with melanoma-associated retinopathy treated with intravenous immunoglobulin. J Neuroophthalmol 28: 23-26, 2008
42. Keltner JL, Thirkill CE, Tyler NK, Roth AM: Management and monitoring of cancer-associated retinopathy. Arch Ophthalmol 110: 48-53, 1992
43. Espandar L, O'Brien S, Thirkill C, Lubecki LA, Esmaeli B: Successful treatment of cancer-associated retinopathy with alemtuzumab. J Neurooncol 83: 295-302, 2007
44. Chan C, O'Day J: Melanoma-associated retinopathy: does autoimmunity prolong survival? Clin Experiment Ophthalmol 29: 235-238, 2001
45. Maeda A, Ohguro H, Nabeta Y, Hirohashi Y, Sahara H, et al: Identification of human antitumor cytotoxic T lymphocytes epitopes of recoverin, a cancer-associated retinopathy antigen, possibly related with a better prognosis in a paraneoplastic syndrome. Eur J Immunol 31: 563-572, 2001